I confirm I am a UK Healthcare Professional (HCP)

This page is dedicated to UK HCPs only. If you are not a UK HCP, you will be directed to the Homepage after clicking on No.

Branded Generics Portfolio

Zentiva has a growing Branded medicines portfolio, covering multiple therapeutic areas. We aim to have the lowest acquisition costs at all times and constantly monitor prices within the UK to ensure we remain competitive.

Potential Savings by switching to Zentiva Products


Zentiva brand INN Average annual pack usage Current annual spend Conversion percentage Potential savings with Zentiva brand

Want to hear more about these products?

  • Affenid

    Affenid® XL
    (methylphenidate hydrochloride)
    prolonged release tablets

    18mg, 27mg, 36mg & 54mg

    Potential cost savings of up to 65% versus Concerta® XL/generic methylphenidate prolonged-release tablets1,2

  • Avenor

    (salmeterol xinofoate + fluticasone propionate)
    metered dose inhaler

    25/50μg, 25/125μg & 25/250μg

    Potential cost savings of up to 56% versus generic salmeterol xinofoate + fluticasone propionate metered dose inhalers1,2

  • Besavar

    Besavar® XL
    (alfuzosin hydrochloride)
    prolonged-release tablets



    Potential cost savings of up to 63% versus generic alfuzosin hydrochloride prolonged-release tablets1,2

  • Blerone

    Blerone® XL
    (tolterodine tartrate)
    prolonged-release capsules


    Potential cost savings of up to 46% versus generic tolterodine tartrate prolonged-release capsules1,2

  • Brancico

    Brancico® XL
    (quetiapine fumarate)
    prolonged-release tablets

    50mg, 150mg, 200mg, 300mg & 400mg

    Potential cost savings of up to 87% versus generic quetiapine fumarate prolonged-release tablets1,2

  • Galzemic

    Galzemic® XL
    (galantamine hydrobromide)
    prolonged-release capsules

    8mg, 16mg & 24mg

    Potential cost savings of up to 63% versus generic galantamine prolonged-release capsules1,2

  • Metyrol

    (alimemazine tartrate)
    oral solution sugar free


    7.5mg/5ml & 30mg/5ml

    Potential cost savings of up to 59% versus equivalent strengths of alimemazine oral solution1,2


  • Metyrol

    Metyrol XL®
    (methylphenidate hydrochloride)
    modified release hard capsules

    10mg, 20mg, 30mg, 40mg & 60mg

    Potential cost savings of up to 28% versus generic methylphenidate modified-release capsules1,2


  • Myloxifin

    (oxycodone hydrochloride / naloxone hydrochloride)
    prolonged-release tablets

    5 mg/2.5mg, 10 mg/5mg , 20 mg/10mg & 40 mg/20mg

    Potential cost savings of up to 29% versus generic oxycodone hydrochloride/naloxone hydrochloride prolonged-release tablets1,2

  • Opiodur

    transdermal patches

    12.5mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr & 100mcg/hr

    Potential cost savings of up to 55% versus generic fentanyl transdermal patches1,2

  • Opiodur

    transdermal patches

    5mcg/hr, 10mcg/hr & 20mcg/hr

    Potential cost savings of up to 70% versus generic buprenorphine transdermal patches1,2

  • Slozem

    (diltiazem hydrochloride)

    120mg, 180mg, 240mg & 300 mg

    Potential cost savings of up to 51% versus generic diltiazem prolonged releases capsule1,2


Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Zentiva via email to UKMedInfo@zentiva.com
or via phone on 0800 090 2408.


1 NHS DM+D browser. services.nhsbsa.nhs.uk/dmd-browser/search
2 NHS Business Services Agency. Drug Tariff Category C price. NHS Electronic Drug Tariff. www.drugtariff.nhsbsa.nhs.uk
Savings are based on October 2023 Drug Tariff

Introductions and Disclaimers:

This calculator calculates the potential cost difference for a ICB/Sub-ICBs/PCN - if Zentiva products are prescribed instead of comparable competitors.

This calculator analyses prescribing data collated by Annaltytic Health, and then uses current DM & D NHS list prices and Drug Tariff reimbursement prices to calculate the cost difference if Zentiva brands are prescribed going forwards instead of the comparable competitors.

Licensed indications may differ to competitor products and additional strengths of products may be available for brands other than the Zentiva ones shown. Please refer to the Summary of Product Characteristics for further information.

Please note this is only an estimation based on current pricing as it is impossible to predict the future pricing of both generic and branded competitors. The source data for this model will be updated on quarterly. The comparisons between packs represents a 12 month supply.

The dashboard analyses data from April 22 to May 23.

This data contains public sector information licensed under the Open Government Licence v3.0.

This site is intended only for healthcare professionals in the United Kingdom.
Date of preparation: October 2023 | Ref: 000604729